NCT03214250 - Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | Biotech Hunter

Enrollment

129

Participants

Timeline

Start Date

July 21, 2017

Primary Completion Date

February 11, 2021

Study Completion Date

February 25, 2022

Conditions

Metastatic Pancreatic Adenocarcinoma

Interventions

DRUG

APX005M

Administer intravenously once every 28-day Cycle

DRUG

Nivolumab

Administer intravenously twice every 28-day cycle

DRUG

Nab-Paclitaxel

Administer intravenously on 3 times every 28-day cycle

DRUG

Gemcitabine

Administer intravenously 3 times every 28-day cycle

Trial Locations (7)

Memorial Sloan Kettering Cancer Center, New York

University of Pennsylvania, Abramson Cancer Center, Philadelphia

M.D. Anderson Cancer Center, Houston

University of California, Los Angeles, Los Angeles

University of California, San Francisco, San Francisco

Stanford University, Stanford

Dana-Farber Cancer Institute, Boston